Download PDF
Thromb Haemost 1995; 74(06): 1578-1582
DOI: 10.1055/s-0038-1649985
Original Article
Animal Models
Schattauer GmbH Stuttgart

Endotoxin-Induced Intravascular Coagulation in Rabbits:Effect of Tissue Plasminogen Activator vs Urokinase on PAI Generation, Fibrin Deposits and Mortality

M J Paloma
The Hematology Service, University Clinic of Navarra, School of Medicine University of Navarra, Pamplona, Spain
,
J A Páramo
The Hematology Service, University Clinic of Navarra, School of Medicine University of Navarra, Pamplona, Spain
,
E Rocha
The Hematology Service, University Clinic of Navarra, School of Medicine University of Navarra, Pamplona, Spain
› Author Affiliations
Further Information

Publication History

Received 14 November 1994

Accepted after resubmission 18 August 1995

Publication Date:
27 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We have evaluated the effect of plasminogen activators (t-PA and urokinase) on an experimental model of disseminated intravascular coagulation (DIC) in rabbits by injection of 20 μg/kg/h of E. coli lipopolysaccharide during 6 h t-PA (0.2 mg/kg and 0.7 mg/kg), urokinase (3000 U/kg/h) and saline (control) were given simultaneously with endotoxin. Results indicated that urokinase and low dose of t-PA significantly reduced the increase of plasminogen activator inhibitor (PAI) activity observed 2 h after endotoxin (p <0.001). High t-PA dose also diminished the PAI levels at 6 h (p <0.0001). A significant reduction of fibrin deposits in kidneys was observed in both t-PA treated groups as compared with findings in the group of rabbits infused with saline solution (p <0.005), whereas urokinase had no significant effect on the extent of fibrin deposition. Finally, the mortality rate in the control group (70%) was reduced to 50% in rabbits receiving high doses of t-PA. In conclusion, treatment with t-PA resulted in reduced PAI generation, fibrin deposits and mortality in endotoxin-treated rabbits

 

  • References

  • 1 Colman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation: a reappraisal. Ann Rev Med 1987; 30: 359-374
    PubMedGoogle Scholar
  • 2 Bick RL. Disseminated intravascular coagulation. Hemat Oncol Clin North America 1992; 6: 1259-1285
    PubMedGoogle Scholar
  • 3 Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol 1978; 93: 527-618
    PubMedGoogle Scholar
  • 4 Gaynor E, Bouvier CA, Spact TH. Vascular lesions: possible pathogenetic basis of the generalized Schwartzman reaction. Science 1970; 170: 986-988
    CrossrefPubMedGoogle Scholar
  • 5 Rickies FR, Rick PD. Structural features of Samonella typhimurium lipopolysaceharide required for activation of tissue factor in human mononuclear cells. J din Invest 1977; 59: 1188-1195
    PubMedGoogle Scholar
  • 6 Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis Arch Intern Med 1992; 152: 1381-1389
    CrossrefPubMedGoogle Scholar
  • 7 Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Ann Rev Med 1987; 38: 417-432
    CrossrefPubMedGoogle Scholar
  • 8 Colucci M, Páramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
    CrossrefPubMedGoogle Scholar
  • 9 Crutchley DJ, Conanan LB. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J Biol Chem 1985; 261: 154-159
    PubMedGoogle Scholar
  • 10 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172
    CrossrefPubMedGoogle Scholar
  • 11 Rocha E, Páramo JA, Fernández FJ, Cuesta B, Hernández M, Paloma MJ. Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 1989; 54: 699-707
    CrossrefPubMedGoogle Scholar
  • 12 Páramo JA, Fernandez FJ, Rocha E. Plasminogen activator inhibitor activity in bacterial infection. Thromb Haemost 1988; 59: 451-454
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Gómez C, Páramo JA, Colucci M, Rocha E. Effect of heparin and/or antithrombin III on the generation of endotoxin-induced plasminogen activator inhibitor. Thromb Haemost 1989; 62: 694-698
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Paloma MJ, Páramo JA, Rocha E. Effect of DDAVP on endotoxin-induced intravascular coagulation in rabbits. Thromb Haemost 1992; 68: 306-309
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981; 291: 590-591
    CrossrefPubMedGoogle Scholar
  • 16 Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1982; 69: 573-580
    CrossrefPubMedGoogle Scholar
  • 17 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration J Clin Invest 1983; 71: 368-376
    CrossrefPubMedGoogle Scholar
  • 18 Agnelli G, Buchanan MR, Fernández F, Boneu B, Hirsh J, Collen D. Hemorrhage-free thrombolysis by tissue plasminogen activator in rabbits: a comparison with streptokinase. Circulation 1985; 72: 178-184
    CrossrefPubMedGoogle Scholar
  • 19 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wingaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266-269
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Páramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor. Relationship to deep venous thrombosis and influence of prophylaxis Thromb Haemost 1985; 54: 713-716
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Bone RC. Sepsis and coagulation. An important link Chest 1992; 101: 594-595
    CrossrefPubMedGoogle Scholar
  • 22 Hajjar KA, Hamel NM, Harpel PC, Nachman RL. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1987; 80: 1712-1719
    CrossrefPubMedGoogle Scholar
  • 23 Colucci M, Páramo JA, Collen D. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo. J Lab Clin Med 1986; 108: 53-59
    PubMedGoogle Scholar
  • 24 Gelerther TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-169
    CrossrefPubMedGoogle Scholar
  • 25 Bevilacqua MP, Schleef RR, Gimbrone MA, Loskutoff DJ. Regulation of the fibrinolytic system of cultured vascular endothelium by interleukin 1. J Clin Invest 1986; 78: 587-591
    CrossrefPubMedGoogle Scholar
  • 26 Van Hinsberg VW M, Kooistra T, Van den Berg EA, Princen HM G, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473
    PubMedGoogle Scholar
  • 27 Krishnamurti C, Barr CF, Hasset MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69: 798-803
    PubMedGoogle Scholar
  • 28 Krishnamurti C, Bolan C, Colleton CA, Reilly TM, Alving BM. Role of plasminogen activator inhibitor-1 in promoting fibrin deposition in rabbits infused with ancrod or thrombin. Blood 1993; 82: 3631-3636
    PubMedGoogle Scholar
  • 29 Sawa H, Fujii S, Sobel B. Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arterioscler Thromb 1992; 12: 1507-1515
    CrossrefPubMedGoogle Scholar
  • 30 Mason JW, Colman RW. The role of Hageman factor in disseminated intravascular coagulation induced by septicemia, neoplasia or liver disease. Thromb Diath Haemorrh 1971; 26: 235-331
    PubMedGoogle Scholar
  • 31 Colman RW. The role of plasma proteases in septic shock. N Engl J Med 1989; 320: 1207-1209
    CrossrefPubMedGoogle Scholar
  • 32 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124
    PubMedGoogle Scholar
  • 33 Agnelli G, Buchanan MR, Fernández F, Hirsh J. The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. Thromb Res 1985; 40: 769-777
    CrossrefPubMedGoogle Scholar
  • 34 Bergstein JM. Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction. Kidney Int 1989; 35: 14-18
    CrossrefPubMedGoogle Scholar
  • 35 Kliman A, Mckay DG. Prevention of the generalized Shwartzman phenomenon by fibrinolysis. Fed Proc 1958; 17: 443-446
    PubMedGoogle Scholar
  • 36 Matsuo O, Mihara H. Threshold phenomena in blood fibrinolysis. Thromb Res 1977; 10: 753-758
    CrossrefPubMedGoogle Scholar
  • 37 Gurewich V, Panned R, Lovie S, Kelley P, Suddith R, Greenlee R. Effective and fibrin specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species J Clin Invest 1984; 73: 1731-1739
    CrossrefPubMedGoogle Scholar